Article
Papillary Thyroid Carcinoma Following Semaglutide Therapy for Metabolic Syndrome: A Case Presentation and Review of Current Evidence
2026-02-09
Abstract excerpt
<title>Abstract</title> <p>Background Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for the management of type 2 diabetes, metabolic syndrome, and obesity. Concerns regarding its potential association with thyroid cancer, particularly medullary thyroid carcinoma have emerged, although current human evidence remains inconclusive. Reports of papillary thyroid carcinoma (PTC) fo...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d1a9be31-15d1-5981-aa7a-c97d03c3bb34
- DOI
- 10.21203/rs.3.rs-8344892/v1
